GENMAB A/S -SP ADR (GMAB) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:GMAB • US3723032062

31.9 USD
-1.13 (-3.42%)
At close: Feb 4, 2026
31.23 USD
-0.67 (-2.1%)
Pre-Market: 2/5/2026, 9:09:07 AM
Fundamental Rating

7

Taking everything into account, GMAB scores 7 out of 10 in our fundamental rating. GMAB was compared to 524 industry peers in the Biotechnology industry. GMAB gets an excellent profitability rating and is at the same time showing great financial health properties. GMAB is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! This makes GMAB very considerable for growth and quality investing!


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • GMAB had positive earnings in the past year.
  • In the past year GMAB had a positive cash flow from operations.
  • In the past 5 years GMAB has always been profitable.
  • In the past 5 years GMAB always reported a positive cash flow from operatings.
GMAB Yearly Net Income VS EBIT VS OCF VS FCFGMAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

  • GMAB's Return On Assets of 21.10% is amongst the best of the industry. GMAB outperforms 97.33% of its industry peers.
  • The Return On Equity of GMAB (25.76%) is better than 97.14% of its industry peers.
  • GMAB has a Return On Invested Capital of 17.11%. This is amongst the best in the industry. GMAB outperforms 96.76% of its industry peers.
  • GMAB had an Average Return On Invested Capital over the past 3 years of 15.20%. This is below the industry average of 18.09%.
  • The 3 year average ROIC (15.20%) for GMAB is below the current ROIC(17.11%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 21.1%
ROE 25.76%
ROIC 17.11%
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
GMAB Yearly ROA, ROE, ROICGMAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

1.3 Margins

  • GMAB has a Profit Margin of 41.35%. This is amongst the best in the industry. GMAB outperforms 97.33% of its industry peers.
  • GMAB's Profit Margin has declined in the last couple of years.
  • The Operating Margin of GMAB (36.85%) is better than 97.90% of its industry peers.
  • In the last couple of years the Operating Margin of GMAB has declined.
  • GMAB has a better Gross Margin (94.27%) than 94.85% of its industry peers.
  • GMAB's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 36.85%
PM (TTM) 41.35%
GM 94.27%
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
GMAB Yearly Profit, Operating, Gross MarginsGMAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), GMAB is creating value.
  • GMAB has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for GMAB has been reduced compared to 5 years ago.
  • GMAB has a worse debt/assets ratio than last year.
GMAB Yearly Shares OutstandingGMAB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
GMAB Yearly Total Debt VS Total AssetsGMAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • GMAB has an Altman-Z score of 11.86. This indicates that GMAB is financially healthy and has little risk of bankruptcy at the moment.
  • GMAB has a better Altman-Z score (11.86) than 83.97% of its industry peers.
  • The Debt to FCF ratio of GMAB is 0.12, which is an excellent value as it means it would take GMAB, only 0.12 years of fcf income to pay off all of its debts.
  • GMAB's Debt to FCF ratio of 0.12 is amongst the best of the industry. GMAB outperforms 95.80% of its industry peers.
  • GMAB has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • GMAB has a Debt to Equity ratio of 0.02. This is comparable to the rest of the industry: GMAB outperforms 43.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.12
Altman-Z 11.86
ROIC/WACC2.34
WACC7.32%
GMAB Yearly LT Debt VS Equity VS FCFGMAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.3 Liquidity

  • GMAB has a Current Ratio of 6.03. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 6.03, GMAB is doing good in the industry, outperforming 62.79% of the companies in the same industry.
  • GMAB has a Quick Ratio of 6.01. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of GMAB (6.01) is better than 63.74% of its industry peers.
Industry RankSector Rank
Current Ratio 6.03
Quick Ratio 6.01
GMAB Yearly Current Assets VS Current LiabilitesGMAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • GMAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 125.90%, which is quite impressive.
  • GMAB shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 28.38% yearly.
  • The Revenue has grown by 24.66% in the past year. This is a very strong growth!
  • Measured over the past years, GMAB shows a very strong growth in Revenue. The Revenue has been growing by 31.16% on average per year.
EPS 1Y (TTM)125.9%
EPS 3Y34.24%
EPS 5Y28.38%
EPS Q2Q%121.44%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-81.55%

3.2 Future

  • GMAB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.30% yearly.
  • The Revenue is expected to grow by 13.38% on average over the next years. This is quite good.
EPS Next Y6.42%
EPS Next 2Y-1.8%
EPS Next 3Y6.27%
EPS Next 5Y9.3%
Revenue Next Year22.77%
Revenue Next 2Y19.6%
Revenue Next 3Y17.39%
Revenue Next 5Y13.38%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
GMAB Yearly Revenue VS EstimatesGMAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
GMAB Yearly EPS VS EstimatesGMAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 13.52 indicates a correct valuation of GMAB.
  • Compared to the rest of the industry, the Price/Earnings ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 97.33% of the companies listed in the same industry.
  • GMAB is valuated cheaply when we compare the Price/Earnings ratio to 28.25, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 18.74 indicates a rather expensive valuation of GMAB.
  • 94.08% of the companies in the same industry are more expensive than GMAB, based on the Price/Forward Earnings ratio.
  • GMAB's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.50.
Industry RankSector Rank
PE 13.52
Fwd PE 18.74
GMAB Price Earnings VS Forward Price EarningsGMAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 96.95% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, GMAB is valued cheaper than 96.37% of the companies in the same industry.
Industry RankSector Rank
P/FCF 16.33
EV/EBITDA 10.62
GMAB Per share dataGMAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • GMAB has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.1
PEG (5Y)0.48
EPS Next 2Y-1.8%
EPS Next 3Y6.27%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for GMAB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GENMAB A/S -SP ADR

NASDAQ:GMAB (2/4/2026, 8:24:39 PM)

Premarket: 31.23 -0.67 (-2.1%)

31.9

-1.13 (-3.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)02-05
Inst Owners44.16%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap19.65B
Revenue(TTM)3.58B
Net Income(TTM)1.48B
Analysts71.85
Price Target28.4 (-10.97%)
Short Float %1.68%
Short Ratio6.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.75%
Min EPS beat(2)25.14%
Max EPS beat(2)36.36%
EPS beat(4)4
Avg EPS beat(4)61.45%
Min EPS beat(4)25.14%
Max EPS beat(4)134.67%
EPS beat(8)6
Avg EPS beat(8)30.99%
EPS beat(12)8
Avg EPS beat(12)16.81%
EPS beat(16)12
Avg EPS beat(16)30.22%
Revenue beat(2)1
Avg Revenue beat(2)-0.2%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)1.09%
Revenue beat(4)2
Avg Revenue beat(4)-1.55%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)1.87%
Revenue beat(8)6
Avg Revenue beat(8)300.02%
Revenue beat(12)10
Avg Revenue beat(12)350.69%
Revenue beat(16)14
Avg Revenue beat(16)264.87%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-1.44%
EPS NQ rev (3m)0.39%
EPS NY rev (1m)3.51%
EPS NY rev (3m)11.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.32%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.48%
Valuation
Industry RankSector Rank
PE 13.52
Fwd PE 18.74
P/S 5.48
P/FCF 16.33
P/OCF 15.42
P/B 3.42
P/tB 5.39
EV/EBITDA 10.62
EPS(TTM)2.36
EY7.4%
EPS(NY)1.7
Fwd EY5.34%
FCF(TTM)1.95
FCFY6.13%
OCF(TTM)2.07
OCFY6.49%
SpS5.82
BVpS9.34
TBVpS5.92
PEG (NY)2.1
PEG (5Y)0.48
Graham Number22.27
Profitability
Industry RankSector Rank
ROA 21.1%
ROE 25.76%
ROCE 21.02%
ROIC 17.11%
ROICexc 37.46%
ROICexgc 140.29%
OM 36.85%
PM (TTM) 41.35%
GM 94.27%
FCFM 33.59%
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
ROICexc(3y)68.77%
ROICexc(5y)79.83%
ROICexgc(3y)104.16%
ROICexgc(5y)104.49%
ROCE(3y)18.68%
ROCE(5y)19.78%
ROICexgc growth 3Y22.66%
ROICexgc growth 5Y11.4%
ROICexc growth 3Y-22.7%
ROICexc growth 5Y-14.09%
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
F-Score7
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.12
Debt/EBITDA 0.09
Cap/Depr 106.94%
Cap/Sales 1.98%
Interest Coverage 243.04
Cash Conversion 91.92%
Profit Quality 81.24%
Current Ratio 6.03
Quick Ratio 6.01
Altman-Z 11.86
F-Score7
WACC7.32%
ROIC/WACC2.34
Cap/Depr(3y)96.21%
Cap/Depr(5y)101.76%
Cap/Sales(3y)1.96%
Cap/Sales(5y)2.38%
Profit Quality(3y)107.36%
Profit Quality(5y)103.53%
High Growth Momentum
Growth
EPS 1Y (TTM)125.9%
EPS 3Y34.24%
EPS 5Y28.38%
EPS Q2Q%121.44%
EPS Next Y6.42%
EPS Next 2Y-1.8%
EPS Next 3Y6.27%
EPS Next 5Y9.3%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-81.55%
Revenue Next Year22.77%
Revenue Next 2Y19.6%
Revenue Next 3Y17.39%
Revenue Next 5Y13.38%
EBIT growth 1Y41.76%
EBIT growth 3Y29.8%
EBIT growth 5Y21.02%
EBIT Next Year56.34%
EBIT Next 3Y28.03%
EBIT Next 5Y19.44%
FCF growth 1Y46.62%
FCF growth 3Y51.06%
FCF growth 5Y42.84%
OCF growth 1Y44.68%
OCF growth 3Y47.08%
OCF growth 5Y41.48%

GENMAB A/S -SP ADR / GMAB FAQ

What is the ChartMill fundamental rating of GENMAB A/S -SP ADR (GMAB) stock?

ChartMill assigns a fundamental rating of 7 / 10 to GMAB.


What is the valuation status for GMAB stock?

ChartMill assigns a valuation rating of 6 / 10 to GENMAB A/S -SP ADR (GMAB). This can be considered as Fairly Valued.


Can you provide the profitability details for GENMAB A/S -SP ADR?

GENMAB A/S -SP ADR (GMAB) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for GMAB stock?

The Price/Earnings (PE) ratio for GENMAB A/S -SP ADR (GMAB) is 13.52 and the Price/Book (PB) ratio is 3.42.


Can you provide the financial health for GMAB stock?

The financial health rating of GENMAB A/S -SP ADR (GMAB) is 8 / 10.